Phase II umbrella study of novel anti-cancer agents in participants with NSCLC who progressed on an anti-PD-1/PD-L1 containing therapy

Trial Identifier: D6185C00001
Sponsor: AstraZeneca
Start Date: December 2017
Primary Completion Date: September 2024
Study Completion Date: September 2026
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AT Innsbruck, AT, 6020
AT Salzburg, AT, 5020
AT Wien, AT, 1140
AT Wien, AT, 1210
CA, AB Edmonton, AB, CA, T6G 1Z2
CA, ON Brampton, ON, CA, L6R 3J7
CA, ON Ottawa, ON, CA, K1H 8L6
CA, ON Toronto, ON, CA, M5G 2M9
CA, QC Montreal, QC, CA, H2X 3E4
DE Berlin, DE, 12203
DE Esslingen a.N., DE, 73730
DE Grosshansdorf, DE, 22927
DE Heidelberg, DE, 69126
ES Barcelona, ES, 08036
ES Madrid, ES, 28034
ES Madrid, ES, 28007
ES Sevilla, ES, 41009
FR Bordeaux, FR, 33076
FR Nantes Cedex 1, FR, 44093
FR Paris, FR, 75877
FR Villejuif, FR, 94800
IL Haifa, IL, 31096
IL Kfar Saba, IL, 95847
IL Petah Tikva, IL, 49100
IL Ramat Gan, IL, 5265601
KR Seoul, KR, 03080
KR Seoul, KR, 05505
KR Seoul, KR, 6351
US, CA Duarte, CA, US, 91010
US, CA Fullerton, CA, US, 92835
US, CA La Jolla, CA, US, 92093
US, CA Los Angeles, CA, US, 90095
US, DC Washington, DC, US, 20016
US, IL Chicago, IL, US, 60637
US, MA Boston, MA, US, 02215
US, MD Baltimore, MD, US, 21224
US, MD Baltimore, MD, US, 21287
US, MO Saint Louis, MO, US, 63110
US, NY New York, NY, US, 10032
US, PA Philadelphia, PA, US, 19111
US, PA Pittsburgh, PA, US, 15232
US, TN Nashville, TN, US, 37203
US, TN Nashville, TN, US, 37212
US, TX Houston, TX, US, 77030
US, VA Fairfax, VA, US, 22031